New Drug Approvals Archive - August 2007
Sanctura (trospium chloride)
New Dosage Form Approved: August 3, 2007
Selzentry (maraviroc) Tablets
Date of Approval: August 6, 2007
Selzentry (maraviroc) is a CCR5 co-receptor antagonist indicated in combination with other antiretroviral agents for the treatment of only CCR5-tropic HIV-1 infection in patients 2 years of age and older.
New Formulation Approved: August 14, 2007
Zingo (lidocaine hydrochloride monohydrate) Dermal PowderJect
Date of Approval: August 16, 2007
Zingo (lidocaine hydrochloride monohydrate) is a needle-free, local anesthetic intradermal injection system, which provides rapid, topical, local analgesia to reduce the pain associated with venous access procedures, such as IV insertions or blood draws.
Reclast (zoledronic acid)
New Indication Approved: August 17, 2007
Patient Population Altered: August 22, 2007
Evithrom (human thrombin)
Date of Approval: August 27, 2007
Evithrom is a highly purified human thrombin used as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques is ineffective or impractical.
Somatuline Depot (lanreotide acetate) Injection - formerly Somatuline Autogel
Date of Approval: August 30, 2007
Somatuline Depot (lanreotide) is a long acting somatostatin analogue indicated for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors.
ACAM2000 (Smallpox (Vaccinia) Vaccine, Live)
Date of Approval: August 31, 2007
ACAM2000 is live vaccinia virus smallpox vaccine intended for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection. ACAM2000 is the first biodefense vaccine to be approved as part of the US response to the 2001 bioterrorism attacks.
Zingo (lidocaine hydrochloride monohydrate)
Patient Population Altered: January 8, 2009
Somatuline Depot (lanreotide acetate)
New Indication Approved: December 16, 2014
New Formulation Approved: November 4, 2016